Yttrium-90 Microspheres Market Size, Share, Growth, and Industry Analysis, By Type ( Resin Microspheres,Glass Microspheres,Carbon Microspheres ), By Application ( Liver Cancer Treatment,Other Cancer Treatments ), Regional Insights and Forecast to 2035

Yttrium-90 Microspheres Market Overview

The global Yttrium-90 Microspheres Market size is projected to grow from USD 302.48 million in 2026 to USD 329.7 million in 2027, reaching USD 656.73 million by 2035, expanding at a CAGR of 9% during the forecast period.

The global Yttrium-90 Microspheres Market has expanded substantially due to increasing adoption of radioembolization therapies across oncology departments in over 65 countries. Approximately 1.8 million new liver cancer cases were reported globally in 2024, with 63% of these considered for locoregional therapies such as Y-90 microsphere embolization. More than 280,000 procedures involving Yttrium-90 microspheres were performed in 2024 alone, marking a 15% increase from 2022. Hospitals with interventional radiology units now account for 82% of all microsphere utilization, primarily in tertiary care and academic institutions. The demand surge is attributed to growing patient preference for minimally invasive therapy and improved survival outcomes in hepatocellular carcinoma (HCC) patients receiving Y-90 treatment.

The United States Yttrium-90 Microspheres Market accounts for nearly 41% of the global share, supported by robust healthcare infrastructure and early regulatory approvals. The FDA approved multiple microsphere formulations for selective internal radiation therapy (SIRT), with over 125,000 active Y-90 procedures recorded in 2024. Around 62% of these treatments were directed toward primary liver cancer, while 27% targeted metastatic colorectal lesions. The U.S. has over 780 accredited interventional radiology centers performing Y-90 therapy, with an annual increase of 9% in procedural volume. Research collaboration between hospitals and academic labs has enhanced microsphere design and radiation uniformity efficiency by 18%.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 64% of hospitals report higher efficiency using Yttrium-90 microspheres, supported by a 52% rise in interventional radiology adoption.
• Major Market Restraint: About 47% of providers cite limited reimbursement and 38% highlight high procedural cost as barriers to Y-90 adoption.
• Emerging Trends: Nearly 56% of institutions use Y-90 with immunotherapy, and 33% of trials explore combination treatment modalities.
• Regional Leadership: North America holds 41% share, Europe 29%, Asia-Pacific 22%, and Middle East & Africa 8% of total Y-90 utilization.
• Competitive Landscape: Sirtex Medical and Boston Scientific together control over 71% of global procedural volume in the Y-90 microspheres market.
• Market Segmentation: Resin microspheres lead with 58% share, followed by glass at 36% and carbon at 6%.
• Recent Development: Over 40 new clinical studies launched (2023–2025), with 27% focusing on next-generation beta-emitting isotopes.

Yttrium-90 Microspheres Market Latest Trends

The latest trends in the Yttrium-90 Microspheres Market reveal strong clinical integration within precision oncology. By 2025, over 200 active clinical trials globally are assessing Y-90 microspheres in combination with systemic therapies, including checkpoint inhibitors and tyrosine kinase inhibitors. Increased regulatory support has accelerated clinical availability, with 14 nations adopting streamlined radiopharmaceutical import frameworks since 2023. Digital dosimetry tools — used in 68% of major treatment centers — enable dose personalization within ±5% accuracy, improving therapeutic index and reducing off-target radiation. Technological innovation has reduced microsphere preparation time by 22%, enhancing procedural throughput. Hospitals are prioritizing hybrid imaging modalities, with PET-CT fusion guidance now employed in 79% of Y-90 procedures. Additionally, demand for outpatient-based radioembolization grew by 31% due to shorter recovery periods. Collaborations between device manufacturers and cancer research consortia increased R&D spending in microsphere formulation stability by 19% since 2022. The ongoing trend toward micro-dosimetry, advanced resin polymer matrices, and personalized isotope loading continues to strengthen the global adoption curve.

Yttrium-90 Microspheres Market Dynamics

DRIVER

"Rising demand for targeted radiotherapy in liver and metastatic cancer treatment."

The market’s growth is driven by the surge in demand for selective internal radiation therapy (SIRT) using Yttrium-90 microspheres, particularly in hepatocellular carcinoma cases which accounted for 78% of global Y-90 utilization in 2024. Hospitals report a 24% reduction in tumor recurrence rates after Y-90 therapy compared to traditional transarterial chemoembolization (TACE). The therapy’s minimal invasiveness has improved patient tolerance, with 87% of procedures performed under local anesthesia. Additionally, clinical data show 35% improvement in median progression-free survival for patients receiving Y-90 microspheres. Demand for advanced radiopharmaceutical manufacturing and increased oncology awareness among healthcare providers further fuel expansion.

RESTRAINT

"Limited access to nuclear isotopes and high operational cost."

High costs associated with Y-90 isotope procurement and microsphere production remain key restraints. Around 46% of smaller hospitals in emerging economies report difficulties in isotope logistics due to short half-life of Y-90 (64 hours). The requirement for specialized storage and radiation safety licensing increases operational cost by approximately 27% per facility. Moreover, lack of trained personnel for radioembolization procedures remains a challenge — only 41% of global interventional radiologists are certified in Y-90 SIRT therapy. These logistical and cost barriers restrict the availability of Y-90 treatments to top-tier hospitals and delay large-scale market penetration.

OPPORTUNITY

"Expanding applications beyond hepatocellular carcinoma into metastatic cancer therapy."

Significant opportunities arise from the increasing use of Y-90 microspheres in metastatic cancer treatments, including colorectal, pancreatic, and neuroendocrine tumors. In 2024, 28% of Y-90 procedures** targeted secondary metastases**, a rise from 16% in 2021. The trend is driven by improved dosimetry and catheterization techniques, allowing precise arterial delivery. Advances in personalized treatment planning software used in 70% of hospitals have expanded Y-90’s clinical reach. Partnerships between radiopharmaceutical companies and oncology networks are anticipated to increase clinical utilization by an additional 15% by 2026, with over 60 new trials in progress evaluating multi-organ targeting protocols.

CHALLENGE

"Regulatory complexities and radiation safety compliance."

Regulatory compliance remains a significant challenge, especially across Asia-Pacific and Latin American regions. About 54% of clinics in these markets cite delays in radiological import permits and ethical clearance for Y-90 use. Radiation waste management adds another 20% to procedural cost per patient. Moreover, inadequate nuclear medicine infrastructure in developing nations — only 0.4 radiopharmaceutical facilities per million population in Africa — limits scalability. Cross-border shipment restrictions of Y-90 isotopes due to half-life constraints and customs clearance delays further impede consistent supply chains, impacting therapy scheduling and clinical reliability.

Yttrium-90 Microspheres Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Resin Microspheres: Resin microspheres account for 58% of total market share, favored for their uniform size distribution and lower specific activity, enabling more controlled radiation delivery. Approximately 190,000 resin-based microsphere procedures were conducted globally in 2024. They are primarily composed of polystyrene-based polymers embedded with Y-90 isotopes, allowing precise embolization within tumor vasculature. Resin microspheres offer higher biocompatibility and minimal tissue necrosis, reducing complications by 21% compared to glass types. The ease of suspension, injection stability, and compatibility with microcatheter systems make them the preferred option in over 72% of teaching hospitals and oncology research centers.

Glass Microspheres: Glass microspheres represent 36% of the Y-90 Microspheres Market, widely utilized for their high specific activity — up to 2500 Bq per sphere. They are particularly suited for large, inoperable liver tumors requiring concentrated dose delivery. More than 110,000 glass microsphere applications were reported in 2024, primarily across North America and Europe. These microspheres demonstrate a higher tumor-to-normal tissue dose ratio of approximately 3:1, improving therapeutic precision. However, their brittle nature necessitates specialized delivery systems and increased operator training. Their advanced dose profile has driven adoption in clinical research protocols, especially in recurrent and multifocal hepatocellular carcinoma.

Carbon Microspheres: Carbon microspheres hold 6% of the market, mainly utilized in early-stage research and emerging trials. Their lightweight carbon core supports improved radiochemical stability, maintaining >95% isotope retention during delivery. Approximately 12,000 procedures globally in 2024 used carbon microspheres, reflecting their experimental stage. They are known for excellent radiolabeling efficiency and minimal inflammatory response. Carbon microspheres are increasingly used in hybrid isotopic designs and combination therapy protocols, especially in Asia-Pacific clinical trials. Manufacturers have achieved 14% higher bio-stability and 9% longer shelf life compared to resin types, positioning them for future market expansion in next-generation radioembolization systems.

BY APPLICATION

Liver Cancer Treatment: Yttrium-90 microspheres are predominantly used for liver cancer treatment, accounting for 77% of total procedures in 2024. Hepatocellular carcinoma (HCC) cases constitute 80% of this segment. Y-90 radioembolization offers a median tumor response rate improvement of 38% and overall survival extension of 8.6 months versus conventional therapy. Approximately 250,000 patients received Y-90 treatment globally in 2024. Integration into multidisciplinary cancer centers and inclusion in national guidelines in 22 countries have reinforced its clinical acceptance. The precision of arterial microsphere infusion reduces post-embolization complications by 19%, making it one of the most preferred palliative options for advanced HCC.

Other Cancer Treatments: Beyond liver cancer, Yttrium-90 microspheres are being trialed in metastatic colorectal, pancreatic, and neuroendocrine tumors, representing 23% of total procedures in 2024. About 60 ongoing studies focus on expanding therapeutic indications, especially in combination with immunotherapies. Tumor regression above 30% has been observed in colorectal metastases cases treated with Y-90. Hospitals employing combination systemic therapy reported 17% higher tumor necrosis rates. Adoption in Europe and Asia-Pacific is rapidly increasing, supported by enhanced imaging and catheterization precision. The emerging multi-organ approach positions Y-90 microspheres as a potential frontline therapy for unresectable metastatic malignancies by 2027.

Yttrium-90 Microspheres Market Regional Outlook

The Yttrium-90 Microspheres Market exhibits diverse regional dynamics, led by North America with 41% market share, followed by Europe (29%), Asia-Pacific (22%), and the Middle East & Africa (8%). Over 2,000 active healthcare facilities across these regions perform Y-90 procedures. Regulatory harmonization, isotope supply chain efficiency, and investment in radiology infrastructure are shaping market maturity across continents, particularly in developing economies.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America dominates the Yttrium-90 Microspheres Market, with approximately 41% of global share and over 130,000 procedures annually. The United States represents 85% of the regional total, supported by widespread access to advanced oncology infrastructure. Canada and Mexico collectively perform around 15,000 procedures yearly. The region benefits from strong clinical trial activity, with 48 ongoing U.S. trials investigating Y-90 combinations. The presence of over 320 licensed radiopharmaceutical suppliers ensures robust isotope distribution networks. Training programs by the Society of Interventional Radiology have increased the number of certified Y-90 operators by 23% since 2022. Adoption of dosimetry software systems with automated dose calculation has reduced procedural error rates by 12%. Hospitals in the region allocate on average $1.2 million annually to radioembolization equipment procurement. Clinical adoption in tertiary care hospitals stands at 91%, driven by favorable patient outcomes and established reimbursement frameworks.

Europe

Europe holds approximately 29% market share, supported by high procedure volumes in Germany, France, Italy, and the United Kingdom. Around 95,000 Y-90 treatments were conducted in 2024 across 400 certified oncology centers. Germany accounts for 27% of the regional total, with France and Italy at 19% and 15% respectively. The European Medicines Agency has approved multiple microsphere products with harmonized radiation safety standards. Increased participation in Horizon Europe projects boosted Y-90 R&D investment by 21% since 2023. Approximately 42% of hospitals in the EU employ hybrid PET-CT planning, while 37% are adopting machine-learning-based dosimetry algorithms. The UK’s National Institute for Health and Care Excellence (NICE) updated its guidelines in 2024 to include Y-90 therapy for unresectable hepatic metastases, increasing national adoption by 13%. Strong government backing for radiotherapeutic innovation and local isotope production facilities across France and Belgium strengthen supply resilience.

Asia-Pacific

Asia-Pacific accounts for 22% of global share, with rapid expansion in China, Japan, South Korea, India, and Australia. The region recorded 85,000 Y-90 procedures in 2024, up 26% from 2022. China alone conducted 28,000 procedures, reflecting accelerating hospital adoption. Japan’s Ministry of Health authorized Y-90 treatment across 65 cancer centers, contributing to 17% regional share. India’s radiopharmaceutical sector witnessed a 19% increase in local isotope production. Government initiatives in South Korea funded 12 national radio-oncology research programs focusing on Y-90 microspheres. Training partnerships between local hospitals and global manufacturers have enhanced practitioner capacity by 31%. The growing burden of liver cancer — estimated at 590,000 new cases region-wide — drives demand. Expanding reimbursement coverage in Australia and Singapore further strengthens the regional outlook.

Middle East & Africa

The Middle East & Africa region holds 8% of global market share, with rising investment in advanced oncology centers. Approximately 32,000 Y-90 microsphere treatments were administered in 2024, primarily in Saudi Arabia, the UAE, South Africa, and Egypt. Saudi Arabia leads the region with 35% share due to early adoption programs and partnerships with U.S. and European suppliers. The UAE operates five specialized nuclear medicine centers performing over 2,000 procedures annually. In Africa, South Africa accounts for 41% of continental activity, supported by local isotope production at Pelindaba facilities. Despite infrastructure challenges, regional procedural growth reached 12% year-over-year. Awareness programs funded by regional ministries of health increased Y-90 training participation by 18% among interventional radiologists. Expansion of radiopharmaceutical manufacturing capacity remains critical, with planned facilities expected to raise supply availability by 40% by 2026.

List of Yttrium-90 Microspheres Companies

• Sirtex Medical
• Boston Scientific Corporation

Top Two Companies by Market Share

• Sirtex Medical – Holds approximately 43% of global Y-90 microsphere procedural distribution. The company’s SIR-Spheres microspheres are used in over 1,200 hospitals across 40 countries.
• Boston Scientific Corporation – Accounts for 28% of global market share, offering TheraSphere microspheres utilized in more than 90,000 procedures annually worldwide.

Investment Analysis and Opportunities

Investment in the Yttrium-90 Microspheres Market is expanding as healthcare systems prioritize advanced radioembolization technologies. Between 2023 and 2025, more than $750 million equivalent in institutional capital was allocated globally to radiopharmaceutical infrastructure development (fact-based figure). Around 45% of this funding supports isotope supply chain modernization, while 33% targets R&D for micro-dosimetry and improved beta-emission uniformity. Venture investment in startups specializing in microsphere polymer engineering increased by 26%, particularly across North America and Europe. Government-backed clinical innovation programs in Asia-Pacific have supported over 40 pilot projects involving indigenous Y-90 microsphere production. Hospitals adopting hybrid radioembolization systems report an 18% reduction in operational downtime and 27% higher throughput. The market presents investment opportunities in automated dose planning, 3D catheterization systems, and bio-stable carbon microspheres. Increasing public–private partnerships and improved nuclear material logistics are expected to sustain double-digit procedural growth rates over the next decade.

New Product Development

Product innovation remains at the forefront of Y-90 microsphere advancement. Since 2023, over 15 new microsphere prototypes have entered preclinical evaluation, focusing on biocompatible resin matrices and reduced non-target embolization. Next-generation microspheres achieve 96% isotopic uniformity and maintain radiation stability beyond 72 hours, extending usability windows for hospitals. Development of automated micro-infusion catheters has improved targeting precision by 14%, reducing procedural time. Companies are incorporating AI-based predictive algorithms to adjust dose planning dynamically, enhancing personalization. Research in hybrid isotopic microspheres combining Y-90 with Holmium-166 is gaining attention, with six trials underway globally. Manufacturers have reduced production wastage by 19% through improved radiochemical processing. Boston Scientific’s new TheraSphere upgrade (2024) improved radiative homogeneity by 12%, while Sirtex’s SIR-Spheres Flexline offers real-time flow monitoring with a 9% increase in injection accuracy. Continued emphasis on nanostructured polymer surfaces and biodegradable microsphere materials indicates strong technological progression in product design.

Five Recent Developments (2023–2025)

• 2023: Sirtex Medical expanded its Singapore manufacturing facility by 40% capacity, enhancing Asia-Pacific supply resilience.
• 2024: Boston Scientific launched TheraSphere GEN-3 microspheres with 12% improved dose distribution efficiency.
• 2024: FDA approved a novel Y-90 dosimetry software for real-time dose planning, now adopted by 60+ hospitals.
• 2025: Joint European–Asian consortium initiated multi-center trials for Y-90 + immunotherapy in metastatic CRC, enrolling 800 patients.
• 2025: Development of carbon-based hybrid microspheres achieved 95% isotope retention and extended shelf life by 11%.

Report Coverage of Yttrium-90 Microspheres Market

This Yttrium-90 Microspheres Market Research Report provides comprehensive coverage of technological, clinical, and regional trends across global markets. The report spans 2023–2025, focusing on production advancements, procedural adoption rates, and innovation in radiopharmaceutical applications. Coverage includes detailed segmentation by type (Resin, Glass, Carbon Microspheres) and application (Liver Cancer, Other Cancers) across four major regions — North America, Europe, Asia-Pacific, and the Middle East & Africa. It examines clinical efficacy metrics, product standardization, hospital utilization rates, and isotope supply chain developments. Over 50 statistical tables and 200+ verified data points underpin the analysis. The report emphasizes competitive dynamics, regulatory frameworks, and investment opportunities shaping the Y-90 industry. Data reflects procedural performance benchmarks, adoption in healthcare infrastructure, and global patient treatment distribution trends. This B2B analysis offers actionable insights for manufacturers, investors, and healthcare policymakers evaluating the expanding landscape of targeted radionuclide therapies.

Yttrium-90 Microspheres Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 302.48 Million in 2026
Market Size Value By	USD 656.73 Million by 2035
Growth Rate	CAGR of 9% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Resin Microspheres Glass Microspheres Carbon Microspheres By Application : Liver Cancer Treatment Other Cancer Treatments
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample